Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

$NUVB
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $NUVB alert in real time by email

Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches

Pending acquisition of AnHeart Therapeutics and expanded leadership strongly positions Nuvation Bio to potentially become a commercial organization by the end of 2025

Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company's commercial strategy and operations, including marketing, sales, and market access.

"We are thrilled to welcome Colleen as Nuvation Bio's first Chief Commercial Officer. She is an accomplished leader who has developed innovative, high-performing commercial organizations for successful product launches, including many leading oncology medicines. Of note, Colleen was one of my commercial superstars at Medivation when we launched XTANDI®," said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. "Colleen joins us at an exciting moment, as we work toward transforming into a late-stage global oncology company with the potential to become commercial-stage by the end of 2025, all while advancing multiple novel therapies for patients with the most difficult-to-treat cancers."

"I am excited to join Nuvation Bio at this critical point in the company's transformation to a commercial-stage organization. I look forward to reuniting with David after our successful time together at Medivation and continuing our shared goal of improving the lives of people with cancer," said Ms. Sjogren. "I have dedicated my career to designing effective commercial organizations for innovative and disruptive new therapies, and I look forward to working with the talented team at Nuvation Bio to build out the company's commercial strategies and capabilities."

Ms. Sjogren most recently served as the Senior Vice President of U.S. Sales at Madrigal Pharmaceuticals, where she developed the commercial sales launch plan for a first-in-class, first-to-market therapy. Previously, she was the Vice President of U.S. Sales, Sales Training, and Meeting Planning at Mirati Therapeutics, where she led the build-out of the field-facing commercial organization for the company's first targeted oncology product launch. Prior to that role, Ms. Sjogren was the Vice President of the National Cell Therapy Team/Sales and Commercial Operations at Kite Pharma, a Gilead company, and held senior leadership roles at Medivation, Human Genome Sciences, Genentech, and Centocor. She received her B.S. and B.A. from Bryant University.

About Nuvation Bio

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com and https://www.linkedin.com/company/nuvationbio/.

Forward Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, the expected closing of the acquisition of AnHeart Therapeutics, the expected timing of establishing a commercial organization and the potential therapeutic benefit of Nuvation Bio's product candidates. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the risk that the acquisition of AnHeart Therapeutics may not close due to the failure of closing conditions to be satisfied or other reasons and the challenges associated with conducting drug discovery and initiating or conducting clinical trials due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-K filed with the SEC on February 29, 2024, under the heading "Risk Factors," and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

Get the next $NUVB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NUVB

DatePrice TargetRatingAnalyst
3/27/2024$1.40 → $10.00Hold → Buy
Jefferies
3/26/2024$5.00Neutral → Buy
BTIG Research
1/6/2023$5.00 → $2.00Buy → Hold
Jefferies
8/2/2022$8.00 → $2.50Outperform → Market Perform
BMO Capital Markets
8/2/2022Buy → Neutral
BTIG Research
5/4/2022$14.00Buy
H.C. Wainwright
10/15/2021$16.00Buy
BTIG Research
More analyst ratings

$NUVB
Press Releases

Fastest customizable press release news feed in the world

See more
  • Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

    Nuvation Bio Inc. (NYSE:NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 10:00 a.m. PT/1:00 p.m. ET in Las Vegas, NV. An audio replay of the fireside chat will be available following the event on the Nuvation Bio website at https://investors.nuvationbio.com/investors/. An archived recording will be available for 90 days following the event. About Nuva

    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

    Nuvation Bio Inc. (NYSE:NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new nonclinical data for taletrectinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25–30, 2025 in Chicago, Illinois. Presentation Overview: Title: Taletrectinib, a next generation selective ROS1 inhibitor, inhibits growth of ROS1 wild-type and ROS1-G2032R xenografts Presenter: Hitisha Patel, Ph.D., Director of Research, Nuvation Bio Session Category: Experimental and Molecular Therapeutics Session Title: Kinase and Phosphatase I

    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

    Nuvation Bio Inc. (NYSE:NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be reported in a mini oral presentation at the European Lung Cancer Congress taking place March 26–29, 2025 in Paris, France. Mini Oral Presentation Overview: Title: Taletrectinib vs crizotinib in ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison Presenter: Misako Nagasaka, M.D., Ph.D., Associate Professor – Division of Hematology and Oncology, UCI Scho

    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$NUVB
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$NUVB
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$NUVB
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$NUVB
SEC Filings

See more

$NUVB
Leadership Updates

Live Leadership Updates

See more
  • Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer

    Global leader with proven financial, operational, and commercial expertise joins Nuvation Bio as the company prepares to transition into a commercial-stage organization Nuvation Bio Inc. (NYSE:NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw strategic segments including commercial systems, multicha

    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

    Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting First patient treated in a Phase 1/2 study of NUV-1511, the company's first drug-drug conjugate (DDC) to enter the clinic, for the treatment of various advanced solid tumors Strong balance sheet with cash, cash equivalents, and marketable securities of $597.0 million as of March 31, 2024 Nuvation Bio Inc. (NYSE:NUVB), a late-stage

    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

    Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches Pending acquisition of AnHeart Therapeutics and expanded leadership strongly positions Nuvation Bio to potentially become a commercial organization by the end of 2025 Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company's commercial strategy and operations, including marketing, sales, and market access. "We are t

    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$NUVB
Financials

Live finance-specific insights

See more
  • Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

    Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025 Acquisition adds taletrectinib, a next-generation, potentially best-in-class ROS1 inhibitor with Breakthrough Therapy Designations currently completing two pivotal studies for the treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC) Acquisition also adds safusidenib, a potentially best-in-class mutant IDH1 inhibitor currently being evaluated in a global Phase 2 study of patients with grades 2 and 3 IDH1-mutant glioma All-stock transaction preserves Nuvation Bio's robust cash balance and enables development of both new

    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Nuvation Bio Reports Full Year 2020 Financial Results and Provides Business Update

    NEW YORK, March 11, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the year ended December 31, 2020 and provided a business update. "Nuvation Bio began a new chapter as a public company following the successful completion of our business combination with Panacea in February. With a strong cash position of approximately $830 million after transaction fees, as well as a recently expanded leadership team and employees dedicated to meaningfully improving the survival and quality of life for people with canc

    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$NUVB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more